SOSV
QuietFiled to raisePrinceton, NJBiotech & pharmaLast fund filed 2026
1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| SOSV Decarbonization Consortium IIFiled to raise in 2026, with no closing reported yet. | 2026 | Indefinite | $0 | 0 |
| SOSV IndieBio Genesis Consortium III | June 2025 | Indefinite | $7M | 5 |
| SOSV HAX GENESIS CONSORTIUMFiled to raise in 2025, with no closing reported yet. | 2025 | Indefinite | $0 | 0 |
| SOSV IRELAND BIOMANUFACTURING FUND | March 2024 | Indefinite | $21M | 4 |
| SOSV INDIEBIO GENESIS CONSORTIUM IIFiled to raise in 2023, with no closing reported yet. | 2023 | Indefinite | $0 | 0 |
| SOSV V INTERNATIONAL | October 2022 | Indefinite | $23M | 14 |
| SOSV V | October 2022 | Indefinite | $131M | 42 |
| SOSV DECARBONIZATION CONSORTIUM | November 2021 | Indefinite | $20M | 11 |
| SOSV IndieBio NY | June 2020 | Indefinite | $44M | 28 |
| SOSV SELECT FUNDFiled to raise in 2020, with no closing reported yet. | 2020 | Indefinite | $0 | 0 |
| SOSV IV-A | October 2018 | Indefinite | $2.1M | 9 |
| SOSV IV | June 2018 | $277M | $277M | 124 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Sean O'sullivanNot on the current fund | Quiet | Biotech & pharma | 1 | 0 |
| Sean O'sulllivan | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Too few companies classified yet to infer a focus. 1 of 1 portfolio companies are classified.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of SOSV’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Novera Ventures | 1 | Prellis Biologics |
| Riverwood Capital | 1 | Prellis Biologics |
| Wrvi Capital | 1 | Prellis Biologics |
A shared board seat: a company where filings name a SOSV partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.